FLOW: Semaglutide for Renal Impairment in Type 2 Diabetes

Phase 3, randomised, double-blind trial in chronic kidney disease (CKD) comparing Semaglutide with Placebo (2 arms). Primary endpoint: Time to First Occurrence of Onset of Persistent ≥50% Reduction in eGFR, Onset of Persistent eGFR <15mL/min/1.73m^2, Initiation of Chronic Renal Replacement Therapy, Renal Death, or CV Death at Week 234. Started Jun 2019; status: completed.